• Search
      • Search Interactions Search Categories
    • Browse
      • Browse Categories Browse Sources
    • Information
      • About Publications Interaction Types & Directionalities Interaction Score & Query Score API Documentation FAQ Known Data Clients News Contact
    • Downloads
      • Data Source Code

RIFAMPIN Drug Record

  • Summary
  • Interactions
  • Claims
  • RIFAMPIN chembl:CHEMBL374478 Approved

    Alternate Names:

    RIFADIN
    RIMACTANE
    RIFAMPIN
    L-5103
    L-5103-LEPETIT
    BA-411661E
    RIFAMPICIN
    NSC-113926
    RIFAMYCIN AMP
    EREMFAT
    NIH-10782
    BA-41166E
    RFP
    3-(((4-METHYL-1-PIPERAZINYL)IMINO)METHYL)RIFAMYCIN SV
    chembl:CHEMBL374478
    chemidplus:13292-46-1
    pubchem.compound:5381226
    rxcui:9384
    drugbank:01045

    Drug Info:

    (1 More Sources)

    Publications:

    Lamba J et al., 2008, Novel single nucleotide polymorphisms in the promoter and intron 1 of human pregnane X receptor/NR1I2 and their association with CYP3A4 expression., Drug Metab Dispos
    Cheng et al., 2009, Rifampicin-activated human pregnane X receptor and CYP3A4 induction enhance acetaminophen-induced toxicity., Drug Metab. Dispos.
    Chen et al., 2006, Roles of rifampicin in drug-drug interactions: underlying molecular mechanisms involving the nuclear pregnane X receptor., Ann. Clin. Microbiol. Antimicrob.
    Suhara Y et al., 2011, Synthesis of novel vitamin K2 analogues with modification at the ω-terminal position and their biological evaluation as potent steroid and xenobiotic receptor (SXR) agonists., J Med Chem
    Karthikeyan C et al., 2015, IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells., Bioorg Med Chem
    Kim SH et al., 2012, TNF-α genetic polymorphism -308G/A and antituberculosis drug-induced hepatitis., Liver Int
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Kim SH et al., 2011, NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption., Eur J Clin Pharmacol
    Kwara A et al., 2014, Factors associated with variability in rifampin plasma pharmacokinetics and the relationship between rifampin concentrations and induction of efavirenz clearance., Pharmacotherapy
    Li LM et al., 2012, SLCO1B1 *15 haplotype is associated with rifampin-induced liver injury., Mol Med Rep
    Chigutsa E et al., 2011, The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications., Antimicrob Agents Chemother
    He YJ et al., 2009, Rifampicin alters atorvastatin plasma concentration on the basis of SLCO1B1 521T>C polymorphism., Clin Chim Acta
    Vavricka et al., 2002, Interactions of rifamycin SV and rifampicin with organic anion uptake systems of human liver., Hepatology
    Wang Y et al., 2017, Association of CYP2B6 gene polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a Chinese population., Infect Genet Evol
    Cho DY et al., 2016, Rifampin enhances cytochrome P450 (CYP) 2B6-mediated efavirenz 8-hydroxylation in healthy volunteers., Drug Metab Pharmacokinet
    Zanger UM et al., 2007, Polymorphic CYP2B6: molecular mechanisms and emerging clinical significance., Pharmacogenomics
    Chan SL et al., 2017, Association and clinical utility of NAT2 in the prediction of isoniazid-induced liver injury in Singaporean patients., PLoS One
    Wu S et al., 2016, Genetic Polymorphisms of Glutathione S-Transferase P1 (GSTP1) and the Incidence of Anti-Tuberculosis Drug-Induced Hepatotoxicity., PLoS One
    He L et al., 2015, Involvement of cytochrome P450 1A1 and glutathione S-transferase P1 polymorphisms and promoter hypermethylation in the progression of anti-tuberculosis drug-induced liver injury: a case-control study., PLoS One
    Pan H et al., 2019, Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population., Pharmacogenet Genomics
    Hennessy EJ et al., 2015, Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity., J Med Chem
    Zanger UM et al., 2008, Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation., Anal Bioanal Chem
    Dutreix C et al., 2014, Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin., Eur J Clin Pharmacol
    Prueksaritanont et al., 2005, Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes., Pharm. Res.
    Wu et al., 1983, Non-competitive inhibition of hepatic and intestinal aryl hydrocarbon hydroxylase activities from rats by rifampin., J. Nat. Prod.
    Nanashima K et al., 2012, Genetic variants in antioxidant pathway: risk factors for hepatotoxicity in tuberculosis patients., Tuberculosis (Edinb)
  • RIFAMPIN   RIPOR2

    Interaction Score: 6.51

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    30720667


    Sources:
    PharmGKB

  • RIFAMPIN   CUX2

    Interaction Score: 3.25

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIFAMPIN   AGBL4

    Interaction Score: 1.63

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIFAMPIN   SLCO1B1

    Interaction Score: 0.38

    Interaction Types & Directionality:
    inhibitor (inhibitory)

    Interaction Info:

    PMIDs:
    24420746 22562052 21709081 19374892 12085361


    Sources:
    PharmGKB

  • RIFAMPIN   NOS2

    Interaction Score: 0.31

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22341855


    Sources:
    PharmGKB

  • RIFAMPIN   GSTP1

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    29036176 27281183 25798582


    Sources:
    PharmGKB

  • RIFAMPIN   CYP2B6

    Interaction Score: 0.27

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    28389387 27053325 17638512


    Sources:
    PharmGKB

  • RIFAMPIN   CYP2C8

    Interaction Score: 0.26

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    15771232


    Sources:
    NCI

  • RIFAMPIN   CYP1B1

    Interaction Score: 0.23

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    6854335


    Sources:
    NCI

  • RIFAMPIN   NR1I2

    Interaction Score: 0.21

    Interaction Types & Directionality:
    agonist (activating)

    Interaction Info:

    PMIDs:
    17925385 19460945 16480505 21561094 25537531


    Sources:
    DTC PharmGKB

  • RIFAMPIN   CYP3A5

    Interaction Score: 0.13

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    26291341 18695978


    Sources:
    DTC PharmGKB

  • RIFAMPIN   TNF

    Interaction Score: 0.1

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22151084


    Sources:
    PharmGKB

  • RIFAMPIN   CYP2C9

    Interaction Score: 0.03

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 20941486


    Sources:
    DTC PharmGKB

  • RIFAMPIN   CYP2C19

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC PharmGKB

  • RIFAMPIN   CYP3A4

    Interaction Score: 0.02

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300 26291341 24839948


    Sources:
    DTC PharmGKB

  • RIFAMPIN   ABCB1

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    PharmGKB

  • RIFAMPIN   CYP1A2

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • RIFAMPIN   CYP2D6

    Interaction Score: 0.01

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    22931300


    Sources:
    DTC

  • RIFAMPIN   AR

    Interaction Score: 0.0

    Interaction Types & Directionality:
    n/a

    Interaction Info:

    PMIDs:
    None found


    Sources:
    DTC

  • DTC: RIFAMPICIN

    • Version: 02-September-2020

    Alternate Names:
    CHEMBL374478 ChEMBL Drug ID

    Drug Info:

    Publications:
    Hennessy EJ et al., 2015, Identification and Optimization of Benzimidazole Sulfonamides as Orally Bioavailable Sphingosine 1-Phosphate Receptor 1 Antagonists with in Vivo Activity., J Med Chem
    Sakatis MZ et al., 2012, Preclinical strategy to reduce clinical hepatotoxicity using in vitro bioactivation data for >200 compounds., Chem Res Toxicol
    Karthikeyan C et al., 2015, IND-2, a pyrimido[1″,2″:1,5]pyrazolo[3,4-b]quinoline derivative, circumvents multi-drug resistance and causes apoptosis in colon cancer cells., Bioorg Med Chem

  • NCI: RIFAMPIN

    • Version: 14-September-2017

    Alternate Names:
    C811 NCI drug code

    Drug Info:

    Publications:
    Prueksaritanont et al., 2005, Comparative effects of fibrates on drug metabolizing enzymes in human hepatocytes., Pharm. Res.
    Wu et al., 1983, Non-competitive inhibition of hepatic and intestinal aryl hydrocarbon hydroxylase activities from rats by rifampin., J. Nat. Prod.

  • PharmGKB: rifampin

    • Version: 18-August-2020

    Alternate Names:

    Drug Info:

    Publications:
    Kim SH et al., 2011, NAT2, CYP2C9, CYP2C19, and CYP2E1 genetic polymorphisms in anti-TB drug-induced maculopapular eruption., Eur J Clin Pharmacol
    Pan H et al., 2019, Association of FAM65B, AGBL4, and CUX2 genetic polymorphisms with susceptibility to antituberculosis drug-induced hepatotoxicity: validation study in a Chinese Han population., Pharmacogenet Genomics
    Dutreix C et al., 2014, Comparison of two endogenous biomarkers of CYP3A4 activity in a drug-drug interaction study between midostaurin and rifampicin., Eur J Clin Pharmacol

  • TTD: Rifampin

    • Version: 2020.06.01

    Alternate Names:
    D0G3DL TTD Drug ID

    Drug Info:

    Publications:

  • ChemblDrugs: chembl:CHEMBL374478

    • Version: ChEMBL_27

    Alternate Names:

    Drug Info:

    Publications:

Disclaimer: This resource is intended for purely research purposes. It should not be used for emergencies or medical or professional advice.

A finding of a drug-gene interaction or potentially druggable category does not necessarily indicate effectiveness (or lack thereof) of any drug or treatment regimen. A finding of no interaction or no potentially druggable category does not necessarily indicate lack of effectiveness of any drug or treatment regimen. Drug-gene interactions or potentially druggable categories are not presented in ranked order of potential or predicted efficacy.

The dgidb.org website does not provide any medical or healthcare products, services or advice, and is not for medical emergencies or urgent situations. IF YOU THINK YOU MAY HAVE A MEDICAL EMERGENCY, CALL YOUR DOCTOR OR 911 IMMEDIATELY. Information contained on this website is not a substitute for a doctor's medical judgment or advice. We recommend that you discuss your specific, individual health concerns with your doctor or health care professional.

DGIdb (v4.2.0 - sha1 afd9f30b) • Last updated 2020-10-21